A Review of Population Pharmacokinetic Models of Posaconazole

References

• Keating GM. Posaconazole. Drugs. 2005;65(11):1553–1567, 1568–1569. doi:10.2165/00003495-200565110-00007
   Web of Science ®Google Scholar
• Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis. 2005;5(12):775–785. doi:10.1016/S1473-3099(05)70297-8
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther. 2005;3(4):467–487. doi:10.1586/14787210.3.4.467
   PubMedGoogle Scholar
• Vicenzi EB, Cesaro S. Posaconazole in immunocompromised pediatric patients. Expert Rev Anti Infect Ther. 2018;16(7):543–553. doi:10.1080/14787210.2018.1490177
   PubMed Web of Science ®Google Scholar
• Assasi N, Grobelna A. Posaconazole for the Prophylaxis and Treatment of Invasive Aspergillosis: A Review of Clinical Effectiveness and Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017.
   Google Scholar
• Lyseng-Williamson KA. Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts. Pharmacoeconomics. 2011;29(3):251–268. doi:10.2165/11206800-000000000-00000
   PubMed Web of Science ®Google Scholar
• Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther. 2007;29(9):1862–1886. doi:10.1016/j.clinthera.2007.09.015
   PubMed Web of Science ®Google Scholar
• John J, Loo A, Mazur S, Walsh TJ. Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients. Expert Opin Drug Metab Toxicol. 2019;15(11):881–895. doi:10.1080/17425255.2019.1671971
   PubMed Web of Science ®Google Scholar
• Ji W, Zhao H, Yang S, Wen Q, He K. Pharmacokinetics and tolerability of intravenous posaconazole in healthy Chinese volunteers: a randomized, open-label and single-dose study. Pharmazie. 2020;75(10):491–493. doi:10.1691/ph.2020.0512
   PubMed Web of Science ®Google Scholar
• Sime FB, Stuart J, Butler J, et al. Pharmacokinetics of intravenous posaconazole in critically ill patients. Antimicrob Agents Chemother. 2018;62(6). doi:10.1128/AAC.00242-18
   Web of Science ®Google Scholar
• Ray J, Campbell L, Rudham S, Nguyen Q, Marriott D. Posaconazole plasma concentrations in critically ill patients. Ther Drug Monit. 2011;33(4):387–392. doi:10.1097/FTD.0b013e31821fb197
   PubMed Web of Science ®Google Scholar
• Mattiuzzi G, Yilmaz M, Kantarjian H, et al. Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. J Infect Chemother. 2015;21(9):663–667. doi:10.1016/j.jiac.2015.05.011
   PubMed Web of Science ®Google Scholar
• Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. Clin Pharmacokinet. 2011;50(11):725–734. doi:10.2165/11592630-000000000-00000
   PubMed Web of Science ®Google Scholar
• Kersemaekers WM, Dogterom P, Xu J, et al. Effect of a high-fat meal on the pharmacokinetics of 300-milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother. 2015;59(6):3385–3389. doi:10.1128/AAC.05000-14
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958–966. doi:10.1128/AAC.01034-08
   PubMed Web of Science ®Google Scholar
• van der Elst KC, Brouwers CH, van den Heuvel ER, et al. Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease. Ther Drug Monit. 2015;37(6):766–771. doi:10.1097/FTD.0000000000000235
   PubMed Web of Science ®Google Scholar
• Alffenaar JW, Van assen S, van der Werf TS, Kosterink JG, Uges DR. Omeprazole significantly reduces posaconazole serum trough level. Clin Infect Dis. 2009;48(6):839. doi:10.1086/597110
   PubMed Web of Science ®Google Scholar
• Dolton MJ, Brüggemann RJ, Burger DM, McLachlan AJ. Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. Antimicrob Agents Chemother. 2014;58(11):6879–6885. doi:10.1128/AAC.03777-14
   PubMed Web of Science ®Google Scholar
• Dekkers B, Bakker M, van der Elst K, et al. Therapeutic drug monitoring of posaconazole: an update. Curr Fungal Infect Rep. 2016;10:51–61. doi:10.1007/s12281-016-0255-4
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2–12. doi:10.1086/508774
   PubMed Web of Science ®Google Scholar
• Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49(6):379–396. doi:10.2165/11319340-000000000-00000
   PubMed Web of Science ®Google Scholar
• Chen L, Krekels E, Verweij PE, Buil JB, Knibbe C, Brüggemann R. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs. 2020;80(7):671–695. doi:10.1007/s40265-020-01306-y
   PubMed Web of Science ®Google Scholar
• Kohl V, Müller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother. 2010;54(1):207–212. doi:10.1128/AAC.01027-09
   PubMed Web of Science ®Google Scholar
• AbuTarif MA, Krishna G, Statkevich P. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr Med Res Opin. 2010;26(2):397–405. doi:10.1185/03007990903485056
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Müller C, Farowski F, et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol. 2012;68(6):987–995. doi:10.1007/s00228-012-1212-y
   PubMed Web of Science ®Google Scholar
• Störzinger D, Borghorst S, Hofer S, et al. Plasma concentrations of posaconazole administered via nasogastric tube in patients in a surgical intensive care unit. Antimicrob Agents Chemother. 2012;56(8):4468–4470. doi:10.1128/AAC.06167-11
   PubMed Web of Science ®Google Scholar
• Petitcollin A, Boglione-Kerrien C, Tron C, et al. Population pharmacokinetics of posaconazole tablets and monte carlo simulations to determine whether all patients should receive the same dose. Antimicrob Agents Chemother. 2017;61(11). doi:10.1128/AAC.01166-17
   PubMed Web of Science ®Google Scholar
• van Iersel M, Rossenu S, de Greef R, Waskin H. A population pharmacokinetic model for a solid oral tablet formulation of posaconazole. Antimicrob Agents Chemother. 2018;62(7). doi:10.1128/AAC.02465-17
   PubMed Web of Science ®Google Scholar
• Boonsathorn S, Cheng I, Kloprogge F, et al. Clinical pharmacokinetics and dose recommendations for posaconazole in infants and children. Clin Pharmacokinet. 2019;58(1):53–61. doi:10.1007/s40262-018-0658-1
   PubMed Web of Science ®Google Scholar
• Wasmann RE, Smit C, van Donselaar MH, et al. Implications for IV posaconazole dosing in the era of obesity. J Antimicrob Chemother. 2020;75(4):1006–1013. doi:10.1093/jac/dkz546
   PubMed Web of Science ®Google Scholar
• Peña-Lorenzo D, Rebollo N, Sánchez-Hernández JG, et al. Population pharmacokinetics of a posaconazole tablet formulation in transplant adult allogeneic stem cell recipients. Eur J Pharm Sci. 2022;168:106049. doi:10.1016/j.ejps.2021.106049
   PubMed Web of Science ®Google Scholar
• Bentley S, Davies JC, Gastine S, Donovan J, Standing JF. Clinical pharmacokinetics and dose recommendations for posaconazole gastroresistant tablets in children with cystic fibrosis. J Antimicrob Chemother. 2021;76(12):3247–3254. doi:10.1093/jac/dkab312
   PubMed Web of Science ®Google Scholar
• Elkayal O, Spriet I, Uyttebroeck A, et al. A population pharmacokinetic modeling and simulation study of posaconazole oral suspension in immunocompromised pediatric patients: a short communication. Ther Drug Monit. 2021;43(4):512–518. doi:10.1097/FTD.0000000000000877
   PubMed Web of Science ®Google Scholar
• Van Daele R, Brüggemann RJ, Dreesen E, et al. Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2021;76(5):1234–1241. doi:10.1093/jac/dkab012
   PubMed Web of Science ®Google Scholar
• Shi C, Xiao Y, Mao Y, Wu J, Lin N. Voriconazole: a review of population pharmacokinetic analyses. Clin Pharmacokinet. 2019;58(6):687–703. doi:10.1007/s40262-019-00735-7
   PubMed Web of Science ®Google Scholar
• Gwee A, Cranswick N, Curtis N. Posaconazole: promising but problematic in practice in pediatric patients. Pediatr Infect Dis J. 2015;34(6):604–606. doi:10.1097/INF.0000000000000635
   PubMed Web of Science ®Google Scholar
• Clark NM, Grim SA, Lynch JR. Posaconazole: use in the prophylaxis and treatment of fungal infections. Semin Respir Crit Care Med. 2015;36(5):767–785. doi:10.1055/s-0035-1562902
   PubMed Web of Science ®Google Scholar
• Morris MI. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm. 2009;66(3):225–236. doi:10.2146/ajhp070532
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–359. doi:10.1056/NEJMoa061094
   PubMed Web of Science ®Google Scholar
• Döring M, Blume O, Haufe S, et al. Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis. 2014;33(4):629–638. doi:10.1007/s10096-013-1998-2
   PubMed Web of Science ®Google Scholar
• Döring M, Eikemeier M, Cabanillas SK, et al. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia. Eur J Clin Microbiol Infect Dis. 2015;34(6):1189–1200. doi:10.1007/s10096-015-2340-y
   PubMed Web of Science ®Google Scholar
• Takpradit C, Wangkittikal C, Rungmaitree S, et al. Antifungal prophylaxis with posaconazole versus fluconazole in children with neutropenia following allogeneic hematopoietic stem cell transplantation: single center experience. J Blood Med. 2021;12:679–689. doi:10.2147/JBM.S319890
   PubMed Web of Science ®Google Scholar
• Jancel T, Shaw PA, Hallahan CW, et al. Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review. J Clin Pharm Ther. 2017;42(1):75–79. doi:10.1111/jcpt.12483
   PubMed Web of Science ®Google Scholar
• Döring M, Cabanillas SK, Klinker H, et al. Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia. Med Mycol. 2017;55(4):375–384. doi:10.1093/mmy/myw091
   PubMed Web of Science ®Google Scholar
• Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy. 2008;28(10):1223–1232. doi:10.1592/phco.28.10.1223
   PubMed Web of Science ®Google Scholar
• Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007;27(12):1627–1636. doi:10.1592/phco.27.12.1627
   PubMed Web of Science ®Google Scholar
• Tang LA, Marini BL, Benitez L, et al. Risk factors for subtherapeutic levels of posaconazole tablet. J Antimicrob Chemother. 2017;72(10):2902–2905. doi:10.1093/jac/dkx228
   PubMed Web of Science ®Google Scholar
• Gautier-Veyret E, Bolcato L, Roustit M, et al. Treatment by posaconazole tablets, compared to posaconazole suspension, does not reduce variability of posaconazole trough concentrations. Antimicrob Agents Chemother. 2019;63(10). doi:10.1128/AAC.00484-19
   PubMed Web of Science ®Google Scholar
• Shields RK, Clancy CJ, Vadnerkar A, et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother. 2011;55(3):1308–1311. doi:10.1128/AAC.01325-10
   PubMed Web of Science ®Google Scholar
• Steinberg KP. Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit. Crit Care Med. 2002;30(6 Suppl):S362–S364. doi:10.1097/00003246-200206001-00005
   PubMed Web of Science ®Google Scholar
• Monnig AA, Prittie JE. A review of stress-related mucosal disease. J Vet Emerg Crit Care. 2011;21(5):484–495. doi:10.1111/j.1476-4431.2011.00680.x
   PubMed Web of Science ®Google Scholar
• Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol. 2005;11(26):4067–4077. doi:10.3748/wjg.v11.i26.4067
   PubMed Web of Science ®Google Scholar
• Panagopoulou P, Roilides E. Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections. Expert Opin Pharmacother. 2022;23(2):175–199. doi:10.1080/14656566.2021.1996562
   PubMed Web of Science ®Google Scholar
• Jia MM, Zhang QW, Qin ZF, et al. Deciphering the relationship between the trough concentration of posaconazole and its efficacy and safety in Chinese patients with hematological disorders. Front Pharmacol. 2020;11:575463. doi:10.3389/fphar.2020.575463
   PubMed Web of Science ®Google Scholar
• Cojutti PG, Candoni A, Lazzarotto D, et al. Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies. Br J Clin Pharmacol. 2018;84(11):2544–2550. doi:10.1111/bcp.13707
   PubMed Web of Science ®Google Scholar
• Allegra S, Fatiguso G, De Francia S, et al. Evaluation of posaconazole pharmacokinetics in adult patients with invasive fungal infection. Biomedicines. 2017;5(4):66. doi:10.3390/biomedicines5040066
   PubMed Web of Science ®Google Scholar
• Jeong W, Snell GI, Levvey BJ, et al. Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations. J Antimicrob Chemother. 2018;73(3):748–756. doi:10.1093/jac/dkx440
   PubMed Web of Science ®Google Scholar
• U.S FDA. Noxafil Instruction. Vol. 2022. U.S FDA; 2022.
   Google Scholar
• Khalil HA, ElKhatib M, Belal TS, El-Yazbi AF, Hamdy DA. Hyperlipidemia alters the pharmacokinetics of posaconazole and vincristine upon co-administration in rats. Drugs R D. 2017;17(2):287–296. doi:10.1007/s40268-017-0178-8
   PubMed Web of Science ®Google Scholar
• Khalil HA, Elnaggar MM, Belal TS, El-Yazbi AF, Hamdy DA. The effect of hyperlipidemia on the pharmacokinetics, hepatic and pulmonary uptake of posaconazole in rat. Eur J Pharm Sci. 2016;91:190–195. doi:10.1016/j.ejps.2016.05.009
   PubMed Web of Science ®Google Scholar
• Emiroglu MY, Esen OB, Bulut M, et al. GGT levels in type II diabetic patients with acute coronary syndrome (does diabetes have any effect on GGT levels in acute coronary syndrome?). Acta Diabetol. 2013;50(1):21–25. doi:10.1007/s00592-010-0208-2
   PubMed Web of Science ®Google Scholar
• Ermis N, Yagmur J, Acikgoz N, et al. Serum gamma-glutamyl transferase (GGT) levels and inflammatory activity in patients with non-dipper hypertension. Clin Exp Hypertens. 2012;34(5):311–315. doi:10.3109/10641963.2011.577485
   PubMed Web of Science ®Google Scholar
• Caravaca-Fontán F, Azevedo L, Bayo MÁ, Gonzales-Candia B, Luna E, Caravaca F. High levels of both serum gamma-glutamyl transferase and alkaline phosphatase are independent predictors of mortality in patients with stage 4–5 chronic kidney disease. Nefrologia. 2017;37(3):267–275. doi:10.1016/j.nefro.2016.11.010
   PubMed Web of Science ®Google Scholar
• Sun D, Liu H, Ouyang Y, Liu X, Xu Y. Serum levels of gamma-glutamyltransferase during stable and acute exacerbations of chronic obstructive pulmonary disease. Med Sci Monit. 2020;26:e927771. doi:10.12659/MSM.927771
   PubMed Web of Science ®Google Scholar
• Fevery J. Bilirubin in clinical practice: a review. Liver Int. 2008;28(5):592–605. doi:10.1111/j.1478-3231.2008.01716.x
   PubMed Web of Science ®Google Scholar
• Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology. 2004;63(10 Suppl 4):S3–S8. doi:10.1212/WNL.63.10_suppl_4.S3
   PubMed Web of Science ®Google Scholar
• Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 2001;299(3):849–857.
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother. 2006;50(5):1881–1883. doi:10.1128/AAC.50.5.1881-1883.2006
   PubMed Web of Science ®Google Scholar
• Krishna G, Ma L, Vickery D, et al. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother. 2009;53(11):4749–4752. doi:10.1128/AAC.00889-09
   PubMed Web of Science ®Google Scholar
• Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57(2):218–222. doi:10.1046/j.1365-2125.2003.01977.x
   PubMed Web of Science ®Google Scholar
• Lin TY, Yang MH, Chang FY. A randomized, Phase I, 3-way crossover study to examine the effects of food on the pharmacokinetics of single doses of 400 mg posaconazole oral suspension in healthy male Taiwanese subjects. Ther Drug Monit. 2013;35(2):223–227. doi:10.1097/FTD.0b013e3182818a56
   PubMed Web of Science ®Google Scholar
• Li H, Wei Y, Zhang S, et al. Pharmacokinetics and safety of posaconazole administered by intravenous solution and oral tablet in healthy Chinese subjects and effect of food on tablet bioavailability. Clin Drug Investig. 2019;39(11):1109–1116. doi:10.1007/s40261-019-00833-1
   PubMed Web of Science ®Google Scholar
• Wei XC, Zhao MF, Li X, Xiao X. Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. Int J Antimicrob Agents. 2020;56(4):106112. doi:10.1016/j.ijantimicag.2020.106112
   PubMed Web of Science ®Google Scholar
• Wiederhold NP. Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections. Clin Pharmacol. 2016;8:1–8. doi:10.2147/CPAA.S60933
   PubMedGoogle Scholar
• Sime FB, Byrne CJ, Parker S, et al. Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients. Crit Care. 2019;23(1):205. doi:10.1186/s13054-019-2483-9
   PubMed Web of Science ®Google Scholar
• Gastine S, Hope W, Hempel G, et al. Pharmacodynamics of posaconazole in experimental invasive pulmonary aspergillosis: utility of serum galactomannan as a dynamic endpoint of antifungal efficacy. Antimicrob Agents Chemother. 2021;65(2). doi:10.1128/AAC.01574-20
   Web of Science ®Google Scholar